Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is ...

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...